ICU SEASTAR MEDICAL HOLDING CORPORATION

SeaStar Medical to Hold Business Update Conference Call on December 11, 2024

SeaStar Medical to Hold Business Update Conference Call on December 11, 2024

DENVER, Dec. 04, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that management will hold a conference call to discuss business progress and updates.

Date/Time:Wednesday, December 11, 4:30 p.m. ET / 1:30 p.m. PT
  
Pre-Registration: Participants can pre-register for the conference call :
  
 Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.
  
Dial In:Those who choose not to pre-register can access the live conference call by dialing the following and requesting the SeaStar Medical call:
 866-777-2509 within the U.S.
 412-317-5413 from outside the U.S.
  

The live webcast of the conference call also will be available . A replay of the call will be available for 48 hours beginning two hours after its completion by dialing 877-344-7529 from within the U.S., 855-669-9658 from Canada or 412-317-0088 from outside the U.S., and entering conference ID 3855739. The webcast will also be archived .

About SeaStar Medical

SeaStar Medical is a commercial-stage medical technology company that is redefining how extracorporeal therapies may reduce the consequences of excessive inflammation on vital organs. SeaStar Medical’s novel technologies rely on science and innovation to provide life-saving solutions to critically ill patients. The Company is developing and commercializing cell-directed extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. For more information visit or visit us on or .

Contact:

Alliance Advisors IR

Jody Cain

(310) 691-7100

# # #



EN
04/12/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SEASTAR MEDICAL HOLDING CORPORATION

 PRESS RELEASE

SeaStar Medical Announces CMS Coverage for Medicare and Medicaid Eligi...

SeaStar Medical Announces CMS Coverage for Medicare and Medicaid Eligible Patients with Cardiorenal Syndrome Awaiting LVAD in Investigational Trial of SCD Therapy Coverage marks SeaStar Medical’s second award by CMS for reimbursement of medical expenses for Medicare and Medicaid patients in a clinical trial Stands out as rare award with less than 100 clinical trials covered annually DENVER, May 28, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ f...

 PRESS RELEASE

SeaStar Medical Reports First Quarter 2025 Financial Results and Provi...

SeaStar Medical Reports First Quarter 2025 Financial Results and Provides Business Updates QUELIMMUNE adoption drives four-fold increase in sequential quarter net revenue NEUTRALIZE AKI trial exceeds 50% enrollment, triggers start of Interim AnalysisWebcast Today at 4:30 pm Eastern Time DENVER, May 14, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today financial results for the three months ended March...

 PRESS RELEASE

SeaStar Medical Reaches Interim Enrollment Target for NEUTRALIZE-AKI P...

SeaStar Medical Reaches Interim Enrollment Target for NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury Indication Has Been Granted FDA Breakthrough Device Designation for Potential PMA Filing DENVER, May 13, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it has successfully reached the halfway point in the NEUTRALIZE-AKI pivotal clinical trial, enablin...

 PRESS RELEASE

SeaStar Medical to Report First Quarter Financial Results on May 14, 2...

SeaStar Medical to Report First Quarter Financial Results on May 14, 2025 DENVER, May 07, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its first quarter financial results after market close on Wednesday, May 14, 2025, and host a webcast and conference call to discuss its financial results and business progress. Date/Time:Wednesday, May 14, 2025, at 4:30 p.m. ET / 2:30 p.m...

 PRESS RELEASE

SeaStar Medical Announces CEO Interview on Benzinga All Access to Occu...

SeaStar Medical Announces CEO Interview on Benzinga All Access to Occur Today at Approximately 10:50 am Eastern Time DENVER, April 30, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today that Eric Schlorff, CEO of SeaStar Medical, will be a featured guest today, Wednesday, April 30th, at approximately 10:50 am Eastern Time on the Benzinga All Access Show. The event will be broadcast live and can be vie...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch